• FStar

    Welcome to F-star

    F-star develops novel bispecific antibodies directed at improving the treatment of serious diseases, with a focus on immuno-oncology.

  • FStar

    Modular Antibody Technology™

    Our robust discovery engine lets us easily “mix-and-match” antibody components to create unique bispecific antibody products.

  • FStar


    F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as “2-in-1” drugs.

Company Overview

F-star is a leader in the discovery and development of novel bispecific antibodies.

We are a biopharmaceutical company focused on developing immuno-oncology bispecific antibody therapeutics through the application of our highly efficient Modular Antibody Technology™ platform.

more about us


  • $100million raised in non-dilutive capital and revenues
  • $34billion Estimated size of the immuno-oncology market in 2024
  • FStar


    Immuno-oncology leverages the body’s natural immune response to fight cancer and is currently one the most exciting areas of research within the biopharmaceutical industry with several key drugs on the market and many in late-stage clinical development.

    Read more about our scientific approach
  • FStar


    An Fcab is derived from the constant (Fc) region of an antibody - the "stem" of an antibody. Natural antibodies bind antigens via the variable (Fab) regions - the "arms" of an antibody. Our platform introduces new antigen binding sites into the Fc region.

    View all technologies

Meet the Team

F-star’s leadership team has decades of combined experience from holding senior-level positions in both pharma and biotech and involving the development of dozens of biologics from target selection to clinical trials.

Find out more about our team